Xenon Pharmaceuticals Inc. — Director's Dealing 2015

Jan 13, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2015-01-08

Reporting Person: AZAB MOHAMMAD (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-08	Common Shares	M	2469	$4.98	Acquired	2469	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-08	Stock Option (Right to Buy)	$4.98	M	2469	Disposed	2015-05-08	Common Shares (2469)	Direct

Footnotes

F1: The exercise price was converted from $6.07 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F2: The shares subject to the option fully vested on January 1, 2008.